ERBB2 and neoplasm: Our data from ErbB2-overexpressing breast cancer cells and syngeneic tumor grafts corroborate that phenformin can block EMT, as evidenced by the upregulation of E-cadherin and concurrent downregulation of EMT markers (Figures 4, 5).